50 related articles for article (PubMed ID: 8967732)
21. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Amadori D; Frassineti GL; De Matteis A; Mustacchi G; Santoro A; Cariello S; Ferrari M; Nascimben O; Nanni O; Lombardi A; Scarpi E; Zoli W
Breast Cancer Res Treat; 1998 Jun; 49(3):209-17. PubMed ID: 9776504
[TBL] [Abstract][Full Text] [Related]
22. [Three cases of colorectal cancer with lung metastasis successfully treated with combination chemotherapy using 5'-DFUR and MMC].
Hosoya Y; Konishi H; Horie H; Ishizuka T; Shitou K; Kojima M; Kashiwagi H; Kanazawa K
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1761-5. PubMed ID: 9757203
[TBL] [Abstract][Full Text] [Related]
23. Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.
Gadducci A; Brunetti I; Muttini MP; Fanucchi A; Dargenio F; Giannessi PG; Conte PF
Eur J Cancer; 1994; 30A(10):1432-5. PubMed ID: 7833097
[TBL] [Abstract][Full Text] [Related]
24. Elevated doses of carmustine and mitomycin C, with lonidamine enhancement and autologous bone marrow transplantation in the treatment of advanced colorectal cancer: results from a pilot study.
Franchi F; Seminara P; Codacci Pisanelli G; Guazzugli Bonaiuti VP; Giovagnorio F; Gualdi G
Eur J Cancer; 1994; 30A(10):1420-3. PubMed ID: 7833095
[TBL] [Abstract][Full Text] [Related]
25. Second line chemotherapy for metastatic colorectal carcinoma.
Gebbia V; Testa A; Cannata G; Tirrito M; Longo A; Sciume C; Valdesi M; Salamone G; Gebbia N; Leo P
Oncol Rep; 1996 Sep; 3(5):867-9. PubMed ID: 21594470
[TBL] [Abstract][Full Text] [Related]
26. Lonidamine in advanced colorectal cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
Passalacqua R; Bisagni G; Bertusi M; Donati D; Buzzi F; Di Costanzo F; Basurto C; Gori S
Tumori; 1989 Jun; 75(3):277-9. PubMed ID: 2672481
[TBL] [Abstract][Full Text] [Related]
27. Clinical modulation of epirubicin resistance by lonidamine in patients with advanced soft-tissue sarcomas.
Lopez M; Carpano S; Dilauro L; Chiatti L; Vici P; Cavaliere F; Gentile P; Citro G
Int J Oncol; 1995 Feb; 6(2):363-7. PubMed ID: 21556546
[TBL] [Abstract][Full Text] [Related]
28. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer.
Poplin EA; LoRusso P; Lokich JJ; Gullo JJ; Leming PD; Schulz JJ; Veach SR; McCulloch W; Baker L; Schein P
Cancer Chemother Pharmacol; 1994; 33(5):415-9. PubMed ID: 8306416
[TBL] [Abstract][Full Text] [Related]
29. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Mansi JL; de Graeff A; Newell DR; Glaholm J; Button D; Leach MO; Payne G; Smith IE
Br J Cancer; 1991 Sep; 64(3):593-7. PubMed ID: 1911204
[TBL] [Abstract][Full Text] [Related]
30. Early observations on the administration of Lonidamine in cancer patients.
Barduagni A; Barduagni M; Di Lauro L; Nardi M; Gallo Curcio C; Tonachella R; Ciottoli GB; Delle Chiaie S
Oncology; 1984; 41 Suppl 1():78-81. PubMed ID: 6717900
[TBL] [Abstract][Full Text] [Related]
31. Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.
Young CW; Currie VE; Kim JH; O'Hehir MA; Farag FM; Kinahan JE
Oncology; 1984; 41 Suppl 1():60-5. PubMed ID: 6717897
[TBL] [Abstract][Full Text] [Related]
32. [Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer].
Ikeda E; Kodaira S; Teramoto T; Okuda M; Takahashi T; Kato T; Yamamoto Y; Isomoto H
Gan To Kagaku Ryoho; 1996 Sep; 23(10):1291-8. PubMed ID: 8831741
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
34. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis.
Vormittag L; Kornek GV; Gruhsmann B; Lenauer A; Föger A; Depisch D; Lang F; Scheithauer W
Anticancer Drugs; 2007 Jul; 18(6):709-12. PubMed ID: 17762401
[TBL] [Abstract][Full Text] [Related]
35. Toxicity and clinical tolerance of lonidamine.
Robustelli della Cuna G; Pedrazzoli P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):18-22. PubMed ID: 2031192
[TBL] [Abstract][Full Text] [Related]
36. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
Cervantes-Madrid D; Romero Y; Dueñas-González A
Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
[TBL] [Abstract][Full Text] [Related]
37. Mitomycin C and lonidamine as second-line treatment of advanced colorectal cancer patients.
Maiello E; Giotta F; Gebbia V; Testa A; Galetta D; Riccardi F; Gebbia N; Colucci G
Anticancer Res; 1996; 16(5B):3177-9. PubMed ID: 8967732
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
